PCOS

COMPARISON BETWEEN PIOGLITAZONE AND METFORMIN FOR OVULATION IN PATIENTS

Authors

  • Ayesha Tariq Nishtar Hospital Multan.
  • Muhammad Azeem Mir Nishtar Hospital Multan
  • Saba Babar DHQ hospital Vehari.
  • Rahat Akhtar Nishtar Hospital Multan

DOI:

https://doi.org/10.29309/TPMJ/2018.25.04.348

Keywords:

Pioglitazone, Metformin, Polycystic Ovarian Syndrome

Abstract

Objectives: The objective is to compare the efficacy of Pioglitazone and
Metformin for ovulation in patients of polycystic ovarian syndrome. Study Design: Randomized
control trial. Setting: Department of Obstetrics and Gynecology, Nishtar Hospital Multan. Period:
January 2017 to June 2017. Methodology: Total number of 66 patients was recruited for this
study. These patients were admitted through or outpatient department. Group A and Group B,
33 patients each. In Group-A patients received metformin while in Group B pioglitazone was
administered. Sample size was calculated using the reference study by Chaudhry I et al (9)
using sample size calculator for two proportions (power of study 80% and confidence interval
95% where prevalence (P1) was 52.17% and (P2) 75%). In group-A patients, Metformin with
dose of 1500 mg per day in three divided doses were given for 6 months. In group B patients,
Pioglitazone 15mg was administered for 6 months. At the end of 6 months, all the patients were
evaluated for efficacy. Results: Total no. of 66 patients was included. The mean age and BMI
of the patients was 29.35±4.01 years and 29.74±2.75 kg/m2 respectively. The age distribution
noted as 66.7% (n=44) patients between 18-30 years and 33.3% (n=22) between 31-37 years.
BMI distribution observed as 45.5% (n=30) patients between 24-29 kg/m2 and 54.5% (n=36)
patients between 30-34 kg/m2. These 100% (n=66) patients were divided into 2 groups equally,
33 in each, i.e. group A and group B. The mean age and BMI of the patients of group A
was 29.42±4.32 years and 29.87±2.58 kg/m2 respectively, while the mean age and BMI of
the patients of group B was 29.27±3.75 years and 29.60±2.94 kg/m2 respectively. Ovulation
was noted as 42.4% (n=14) and 45.5% (=15) for groups A and B respectively. No association
was found between efficacy and ovulation (p=0.849). Efficacy was notes as 69.7% (n=23) and
72.7% (n=24) for group A and group B respectively. No difference was found between efficacy
and groups i.e. between pioglitazone and metformin for ovulation in patients of polycystic ovary
syndrome (p=0.786). Similarly, no association was found between efficacy with age (p=0.442)
and BMI (p=0.728), after applying the chi-square. Conclusion: This study concludes that
Pioglitazone is as much effective as metformin for ovulation induction in women with PCOS.

Author Biographies

Ayesha Tariq, Nishtar Hospital Multan.

MBBS
House Officer

Muhammad Azeem Mir, Nishtar Hospital Multan

MBBS
House Officer

Saba Babar, DHQ hospital Vehari.

MBBS
House Officer

Rahat Akhtar, Nishtar Hospital Multan

MBBS, FCPS
Woman Medical Officer

Downloads

Published

2018-04-10